BioCentury
ARTICLE | Company News

Oxford BioMedica, Viragen, Roslin Institute deal

July 2, 2007 7:00 AM UTC

VRA will halt further development of its OVA avian transgenic technology for manufacturing therapeutic proteins and terminate related research and license agreements with OXB and the institute. OVA us...